Page 10 - Presentation

Conclusions

• Gem-Doce associated with less HG recurrences and treatment

discontinuation compared to BCG in first line setting at 2years.

• 86 patients (49.4%) in the BCG group and 72 patients (52.2%) in the

gemcitabine and docetaxel group reported experiencing AEs

• Notes/Limitations:

➢ Retrospective design (bias, confounding)

➢ 1/3 BCG use and limited maintenance schedule

➢ Which will have more durable response beyond 2yrs?

➢ Shorter f/u of Gem/Doce group

➢ Inability to determine progression/CSS/OS BRIDGE Trial

NCT05538663

Eastern Cooperative Grp